|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ
and Wang TC: Oesophageal adenocarcinoma and gastric cancer: Should
we mind the gap? Nat Rev Cancer. 16:305–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lordick F and Janjigian YY: Clinical
impact of tumour biology in the management of gastroesophageal
cancer. Nat Rev Clin Oncol. 13:348–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrelli F, Zaniboni A, Coinu A, Cabiddu
M, Ghilardi M, Sgroi G and Barni S: Cisplatin or not in advanced
gastric cancer: A systematic review and meta-analysis. PLoS One.
8:e830222013. View Article : Google Scholar
|
|
7
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen DJ, Chen W, Jiang H, Yang H, Wang YC
and Chen JH: Downregulation of DOCK1 sensitizes bladder cancer
cells to cisplatin through preventing epithelial-mesenchymal
transition. Drug Des Devel Ther. 10:2845–2853. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:212016. View Article : Google Scholar
|
|
10
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen QY, Jiao DM, Wang J, Hu H, Tang X,
Chen J, Mou H and Lu W: miR-206 regulates cisplatin resistance and
EMT in human lung adenocarcinoma cells partly by targeting MET.
Oncotarget. 7:24510–24526. 2016.PubMed/NCBI
|
|
13
|
Wang LL, Zhang XH, Zhang X and Chu JK:
MiR-30a increases cisplatin sensitivity of gastric cancer cells
through suppressing epithelial-to-mesenchymal transition (EMT). Eur
Rev Med Pharmacol Sci. 20:1733–1739. 2016.PubMed/NCBI
|
|
14
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang W, Cheng AS, Yu J and To KF: Emerging
role of Hippo pathway in gastric and other gastrointestinal
cancers. World J Gastroenterol. 22:1279–1288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong AW, Meng Z and Guan KL: The Hippo
pathway in intestinal regeneration and disease. Nat Rev
Gastroenterol Hepatol. 13:324–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yue G, Sun X, Gimenez-Capitan A, Shen J,
Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly
expressed in gastric signet ring cell carcinoma. BioMed Res Int.
2014:3930642014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP,
Xue CH, Yang K and Tian ZB: Effects of the hippo signaling pathway
in human gastric cancer. Asian Pac J Cancer Prev. 14:5199–5205.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim MH and Kim J, Hong H, Lee SH, Lee JK,
Jung E and Kim J: Actin remodeling confers BRAF inhibitor
resistance to melanoma cells through YAP/TAZ activation. EMBO J.
35:462–478. 2016. View Article : Google Scholar :
|
|
20
|
Tian T, Li A, Lu H, Luo R, Zhang M and Li
Z: TAZ promotes temozolomide resistance by upregulating MCL-1 in
human glioma cells. Biochem Biophys Res Commun. 463:638–643. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang
W, Qi B, Qiu J, Song X, Ye J, et al: The Hippo transducer TAZ
promotes epithelial to mesenchymal transition and cancer stem cell
maintenance in oral cancer. Mol Oncol. 9:1091–1105. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X,
Chen S, Chen C and Wang Z: Acquisition of epithelial-mesenchymal
transition is associated with Skp2 expression in
paclitaxel-resistant breast cancer cells. Br J Cancer.
110:1958–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou
Y, Chen C, Yang Y, Miele L, Sarkar FH, et al: Chemoresistance to
gemcitabine in hepatoma cells induces epithelial-mesenchymal
transition and involves activation of PDGF-D pathway. Oncotarget.
4:1999–2009. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kong D, Wang Z, Sarkar SH, Li Y, Banerjee
S, Saliganan A, Kim HR, Cher ML and Sarkar FH: Platelet-derived
growth factor-D overexpression contributes to
epithelial-mesenchymal transition of PC3 prostate cancer cells.
Stem Cells. 26:1425–1435. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Z, Zheng N, Wang L, Hou Y, Zhou X and
Wang Z: Rottlerin exhibits antitumor activity via down-regulation
of TAZ in non-small cell lung cancer. Oncotarget. 8:7827–7838.
2017.
|
|
27
|
Tan Y, Qin S, Hou X, Qian X, Xia J, Li Y,
Wang R, Chen C, Yang Q, Miele L, et al: Proteomic-based analysis
for identification of proteins involved in 5-fluorouracil
resistance in hepatocellular carcinoma. Curr Pharm Des. 20:81–87.
2014. View Article : Google Scholar
|
|
28
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and
overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33.
2011. View Article : Google Scholar
|
|
29
|
Mallini P, Lennard T, Kirby J and Meeson
A: Epithelial-to-mesenchymal transition: What is the impact on
breast cancer stem cells and drug resistance. Cancer Treat Rev.
40:341–348. 2014. View Article : Google Scholar
|
|
30
|
Xie D, Cui J, Xia T, Jia Z, Wang L, Wei W,
Zhu A, Gao Y, Xie K and Quan M: Hippo transducer TAZ promotes
epithelial mesenchymal transition and supports pancreatic cancer
progression. Oncotarget. 6:35949–35963. 2015.PubMed/NCBI
|
|
31
|
Xiao H, Jiang N, Zhou B, Liu Q and Du C:
TAZ regulates cell proliferation and epithelial-mesenchymal
transition of human hepatocellular carcinoma. Cancer Sci.
106:151–159. 2015. View Article : Google Scholar :
|
|
32
|
Piskareva O, Harvey H, Nolan J, Conlon R,
Alcock L, Buckley P, Dowling P, Henry M, O'Sullivan F, Bray I, et
al: The development of cisplatin resistance in neuroblastoma is
accompanied by epithelial to mesenchymal transition in vitro.
Cancer Lett. 364:142–155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang D, Duan H, Huang H, Tong X, Han Y,
Ru G, Qu L, Shou C and Zhao Z: Cisplatin resistance in gastric
cancer cells is associated with HER2 upregulation-induced
epithelial-mesenchymal transition. Sci Rep. 6:205022016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song J and Li Y: miR-25-3p reverses
epithelial-mesenchymal transition via targeting Sema4C in
cisplatin-resistance cervical cancer cells. Cancer Sci. 108:23–31.
2017. View Article : Google Scholar
|
|
36
|
Sun Y, Guan Z, Liang L, Cheng Y, Zhou J,
Li J and Xu Y: NF-κB signaling plays irreplaceable roles in
cisplatin-induced bladder cancer chemoresistance and tumor
progression. Int J Oncol. 48:225–234. 2016.
|
|
37
|
Liu WH, Chen MT, Wang ML, Lee YY, Chiou
GY, Chien CS, Huang PI, Chen YW, Huang MC, Chiou SH, et al:
Cisplatin-selected resistance is associated with increased motility
and stem-like properties via activation of STAT3/Snail axis in
atypical teratoid/rhabdoid tumor cells. Oncotarget. 6:1750–1768.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu H, Gu Y, Yin J, Zheng G, Wang C, Zhang
Z, Deng M, Liu J, Jia X and He Z: SET-mediated NDRG1 inhibition is
involved in acquisition of epithelial-to-mesenchymal transition
phenotype and cisplatin resistance in human lung cancer cell. Cell
Signal. 26:2710–2720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu
SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin
cytotoxicity in non-small cell lung cancer cells. Asian Pac J
Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar
|
|
40
|
Wang H, Zhang G, Zhang H, Zhang F, Zhou B,
Ning F, Wang HS, Cai SH and Du J: Acquisition of
epithelial-mesenchymal transition phenotype and cancer stem
cell-like properties in cisplatin-resistant lung cancer cells
through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol.
723:156–166. 2014. View Article : Google Scholar
|
|
41
|
Tan J, You Y, Xu T, Yu P, Wu D, Deng H,
Zhang Y and Bie P: Par-4 downregulation confers cisplatin
resistance in pancreatic cancer cells via PI3K/Akt
pathway-dependent EMT. Toxicol Lett. 224:7–15. 2014. View Article : Google Scholar
|
|
42
|
Yu M, Zhang C, Li L, Dong S, Zhang N and
Tong X: Cx43 reverses the resistance of A549 lung adenocarcinoma
cells to cisplatin by inhibiting EMT. Oncol Rep. 31:2751–2758.
2014.PubMed/NCBI
|
|
43
|
Tièche CC, Peng RW, Dorn P, Froment L,
Schmid RA and Marti TM: Prolonged pemetrexed pretreatment augments
persistence of cisplatin-induced DNA damage and eliminates
resistant lung cancer stem-like cells associated with EMT. BMC
Cancer. 16:1252016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a induces cisplatin
resistance of a human gastric cancer cell line via targeting CYLD.
Mol Med Rep. 14:1742–1750. 2016.PubMed/NCBI
|
|
45
|
Zhao J, Nie Y, Wang H and Lin Y: MiR-181a
suppresses autophagy and sensitizes gastric cancer cells to
cisplatin. Gene. 576:828–833. 2016. View Article : Google Scholar
|
|
46
|
Wen L, Cheng F, Zhou Y and Yin C: MiR-26a
enhances the sensitivity of gastric cancer cells to cisplatin by
targeting NRAS and E2F2. Saudi J Gastroenterol. 21:313–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zuo QF, Zhang R, Li BS, Zhao YL, Zhuang Y,
Yu T, Gong L, Li S, Xiao B and Zou QM: MicroRNA-141 inhibits tumor
growth and metastasis in gastric cancer by directly targeting
transcriptional co-activator with PDZ-binding motif, TAZ. Cell
Death Dis. 6:e16232015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou X, Su J, Feng S, Wang L, Yin X, Yan J
and Wang Z: Antitumor activity of curcumin is involved in
down-regulation of YAP/TAZ expression in pancreatic cancer cells.
Oncotarget. 7:79076–79088. 2016.PubMed/NCBI
|
|
49
|
Zhang J, Tian XJ and Xing J: Signal
transduction pathways of EMT induced by TGF-β, SHH, and WNT and
their crosstalks. J Clin Med. 5:52016. View Article : Google Scholar
|
|
50
|
Guo L, Zheng J, Zhang J, Wang H, Shao G
and Teng L: Knockdown of TAZ modifies triple-negative breast cancer
cell sensitivity to EGFR inhibitors by regulating YAP expression.
Oncol Rep. 36:729–736. 2016.PubMed/NCBI
|
|
51
|
Gao Y, Shi Q, Xu S, Du C, Liang L, Wu K,
Wang K, Wang X, Chang LS, He D, et al: Curcumin promotes KLF5
proteasome degradation through downregulating YAP/TAZ in bladder
cancer cells. Int J Mol Sci. 15:15173–15187. 2014. View Article : Google Scholar : PubMed/NCBI
|
